首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1478072

全球猝睡症藥物市場規模、佔有率、成長分析、依發作性睡病類型、治療方法、最終用戶 - 產業預測 2024-2031

Global Narcolepsy Drugs Market Size, Share, Growth Analysis, By Narcolepsy Type, By Therapeutics, By End User - Industry Forecast 2024-2031

出版日期: 2024年05月06日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球猝睡症藥物市場預計將從2022 年的32.1 億美元成長，從2023 年的35.2 億美元成長到2031 年達到73.2 億美元，在預測期內（2024-2031 年）複合年成長率為9.60 %。

猝睡症藥物市場主要是由人口老化所推動的，他們更容易患各種需要醫療照護的慢性和急性疾病。此外，猝睡症的增加、生活方式的改變以及導致猝睡症的壓力水平增加等因素預計將在預測期內推動市場擴張。此外，研究工作的增加、醫療保健支出的增加和醫療基礎設施的增強預計將有助於未來幾年猝睡症藥物市場的顯著成長。中樞性嗜睡症的症狀，例如晝夜節律延遲和睡眠增加，可以透過遠距辦公和改善睡眠條件來控制，從而進一步推動對猝睡症治療的需求。然而，高昂的治療和診斷成本以及對猝睡症現有治療方法的認知有限等課題可能會阻礙市場擴張。此外，不利的報銷環境也限制了市場的成長。此外，製藥公司標靶治療研發的營業收入機會減少，在整個預測期內對猝睡症治療市場構成課題。儘管存在這些課題，但由於發作性睡患者病率的增加以及開發有效治療方法的持續努力，預計市場將顯著成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2023 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率 (%), 2023

主要公司簡介

Jazz Pharmaceuticals
Teva Pharmaceutical Industries
Novartis
Mylan NV
Shire Pharmaceuticals (acquired by Takeda Pharmaceutical Company Limited)
Ligand Pharmaceuticals
Bioprojet SCR
Arena Pharmaceuticals
Avadel Pharmaceuticals
Graymark Healthcare
Balance Pharmaceuticals
Theravance Biopharma
Biocodex
Flamel Technologies
Otsuka Pharmaceutical
Biogen
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals

簡介目錄

Product Code: SQMIG35I2087

Global narcolepsy drugs market is expected to rise from USD 3.21 billion in 2022 and rise from USD 3.52 billion in 2023 to reach USD 7.32 billion by 2031, by rising at a CAGR of 9.60% during the forecast period (2024- 2031).

The narcolepsy drugs market is primarily driven by the aging population, who are more susceptible to various chronic and acute diseases requiring medical care. Additionally, factors such as the rise in narcoleptic diseases, changing lifestyles, and increased stress levels contributing to narcolepsy disorder are projected to fuel market expansion during the forecast period. Moreover, increased research efforts, rising healthcare expenditure, and enhanced medical infrastructure are expected to contribute to significant growth in the narcolepsy drugs market in the coming years. Symptoms of central hypersomnia, such as circadian delay and increased sleep, can be managed through teleworking and improved sleep conditions, further driving demand for narcolepsy treatments. However, challenges such as high treatment and diagnostic costs, as well as limited awareness about available treatments for narcolepsy, may hinder market expansion. Additionally, an unfavorable reimbursement environment poses a constraint to market growth. Furthermore, decreased operating revenue opportunities for targeted therapy research and development by pharmaceutical companies present challenges to the narcolepsy treatment market throughout the forecast period. Despite these challenges, the market is expected to witness significant growth driven by the increasing prevalence of narcolepsy and ongoing efforts to develop effective therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the global narcolepsy drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Drugs Market Segmental Analysis

Global narcolepsy drugs market is segmented based on the narcolepsy type, therapeutics, end user and region. By narcolepsy type, the market is segmented into cataplexy, and daytime extreme sleepiness. By therapeutics, the market is segmented into psychostimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitors, and central nervous system stimulants. By end user segment is segmented into hospitals, and diagnostic centres. By region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and MEA.

Drivers of the Global Narcolepsy Drugs Market

The narcolepsy market is experiencing significant growth from 2023 to 2030, driven by growing awareness of narcolepsy treatment options. The increasing adoption of modafinil, which has fewer adverse effects compared to other stimulants, is further fueling demand for narcolepsy treatment. As a result, the adoption of appropriate therapies plays a crucial role in preventing and managing narcolepsy, contributing to the market's expansion.

Restraints in the Global Narcolepsy Drugs Market

The lack of awareness surrounding narcolepsy symptoms often leads to misdiagnosis, with symptoms being mistaken for those of other mental and neurological conditions. Consequently, medications such as antiepileptics and psychiatric drugs are often prescribed, posing potential risks to the health of children and adolescents.

Market Trends of the Global Narcolepsy Drugs Market

The expanding prevalence of narcolepsy across diverse population groups globally serves as a significant growth catalyst for the narcolepsy market, with the escalating incidence of sleep disorders and hallucinations bolstering demand for narcolepsy drugs on a global scale. Moreover, the projected increase in obesity rates worldwide is poised to further fuel the market's expansion. Anticipated governmental initiatives aimed at raising awareness about narcolepsy are expected to drive demand for narcolepsy products in the foreseeable future. Hospital-based end-use is forecasted to be the primary contributor to market growth, fueled by the growing number of narcolepsy patients seeking treatment in these facilities.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Narcolepsy Drugs Market by Narcolepsy Type

Market Overview
Cataplexy
and Daytime Extreme Sleepiness.

Global Narcolepsy Drugs Market by Therapeutics

Market Overview
Psychostimulants
Tricyclic Antidepressants
Sodium Oxybate
Selective Serotonin Reuptake Inhibitors
Central Nervous System Stimulants.

Global Narcolepsy Drugs Market by End User

Market Overview
Hospitals
and Diagnostic Centres.a

Global Narcolepsy Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Jazz Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shire Pharmaceuticals (acquired by Takeda Pharmaceutical Company Limited)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioprojet SCR
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arena Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avadel Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graymark Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Balance Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocodex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flamel Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments